Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

NewAmsterdam Pharma (NAMS) Return on Capital Employed (2024 - 2025)

Historic Return on Capital Employed for NewAmsterdam Pharma (NAMS) over the last 2 years, with Q3 2025 value amounting to 0.27%.

  • NewAmsterdam Pharma's Return on Capital Employed rose 1900.0% to 0.27% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.27%, marking a year-over-year increase of 1900.0%. This contributed to the annual value of 0.35% for FY2024, which is 1500.0% up from last year.
  • According to the latest figures from Q3 2025, NewAmsterdam Pharma's Return on Capital Employed is 0.27%, which was up 1900.0% from 0.22% recorded in Q2 2025.
  • NewAmsterdam Pharma's 5-year Return on Capital Employed high stood at 0.22% for Q2 2025, and its period low was 0.55% during Q1 2024.